Abstract
Background
Recent data indicate that in multiple sclerosis disease onset before the age of 16 is more common than previously assumed. However, current therapeutic options are limited to the treatment of acute attacks in these patients. Glatiramer acetate has been successfully applied in adults with relapsing-remitting multiple sclerosis, but there are no data available about the use of glatiramer acetate in childhood and juvenile onset multiple sclerosis.
Methods
Seven patients with relapsing-remitting multiple sclerosis and disease onset between 9 and 16 years of age were treated with daily subcutaneous injection of 20 mg glatiramer acetate (Copaxone). Patients were followed for 24 months. Treatment was initiated in all patients before the age of 18.
Results
The use of glatiramer acetate in our cohort of early onset multiple sclerosis patients was safe and well tolerated. Two out of seven patients remained relapse-free during the two year period. Clinical disability as measured by the EDSS remained stable in three out of seven patients.
Conclusion
Due to the small number of patients the efficacy of the treatment has to be interpreted with caution. However, there might be a more pronounced treatment benefit in patients with low disability at treatment initiation and early treatment onset.
Key words
Multiple sclerosis - childhood-onset - glatiramer acetate
References
-
1
Adams A B, Tyor W R, Holden K R.
Interferon beta-1 b and childhood multiple sclerosis.
Pediatr Neurol.
1999;
21
481-483
-
2
Balassy C, Bernert G, Wöber-Bingöl C, Csapo B, Kornek B, Szeles J. et al .
Long-term MRI observation of childhood-onset multiple sclerosis.
Neuropediatrics.
2001;
32
28-37
-
3
Boiko A, Vorobeychik G, Paty D, Devonshire V, Sadovnick D, University of British Columbia Clinic Neurologists M S.
Early onset multiple sclerosis: a longitudinal study.
Neurology.
2002;
59
1006-1010
-
4
Brück W, Bitsch A, Kolenda H, Brück Y, Stiefel M, Lassmann H.
Inflammatory central nervous system demyelination: Correlation of magnetic resonance imaging with lesion pathology.
Ann Neurol.
1997;
42
783-793
-
5
Cole G F, Stuart C A.
A long-term perspective on childhood multiple sclerosis.
Dev Med Child Neurol.
1995;
37
661-666
-
6
Comi G, Filippi M, Wolinsky J S. and the European/Canadian Glatiramer Acetate Study Group .
European/Canadian multicenter, double-blind, randomised, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis.
Ann Neurol.
2001;
49
290-297
-
7
Comi G, Filippi M, Barkhof F, Durelli L, Edan G, Fernandez O. et al .
Early Treatment of Multiple Sclerosis Study Group. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study.
Lancet.
2001;
357
1576-1582
-
8
Dale R C, de Sousa C, Chong W K, Cox T CS, Harding B, Neville B GR.
Acute disseminated encephalomyelitis, multiphasic disseminated encephalomyelitis and multiple sclerosis in children.
Brain.
2000;
123
2407-2422
-
9
Duquette P, Murray T J, Pleines J.
Multiple sclerosis in childhood: clinical profile in 125 patients.
J Pediatr.
1987;
111
359-363
-
10 Ebers G. The natural history of multiple sclerosis. Compston A, Ebers G, Lassmann H, McDonalds I, Matthews B, Weherle H McAlpines' Multiple Sclerosis. 3rd ed. London; Churchill Livingstone 1998: 191-221
-
11
Filippi M, Rovaris M, Rocca M A, Sormani M P, Wolinsky J S, Comi G. and the European Canadian Glatiramer Acetate Study Group .
Glatiramer acetate reduces the proportion of new MS lesions evolving into “black holes”.
Neurology.
2001;
57
731-733
-
12
Filippi M, Grossman R I.
MRI techniques to monitor MS evolution: The present and the future.
Neurology.
2002;
58
1147-1153
-
13
Ghezzi A, Deplano V, Faroni J, Grasso M G, Liguori M, Marrosu G. et al .
Multiple sclerosis in childhood: clinical features of 149 cases.
Mult Scler.
1997;
3
43-46
-
14
Hanefeld F A.
Characteristics of childhood multiple sclerosis.
Int MSJ.
1994;
1
90-97
-
15
Jacobs L D, Beck R W, Simon J H, Kinkel R P, Brownscheidle C M, Murray T J. et al .
Intramuscular interferon beta-1 a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group.
N Engl J Med.
2000;
343
898-904
-
16
Johnson K P, Brooks B R, Cohen J A, Ford C C, Goldstein J, Lisak R P. et al .
Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial.
Neurology.
1995;
45
1268-1276
-
17
Johnson K P, Brooks B R, Cohen J A, Ford C C, Goldstein J, Lisak R P. et al .
Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability.
Neurology.
1998;
50
701-708
-
18
Johnson K P, Brooks B R, Ford C C, Goodman A, Guarnaccia J, Lisak R P. and the Copolymer Multiple Sclerosis Study Group .
Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years.
Mult Scler.
2000;
6
255-266
-
19
Kurtzke J F.
Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS).
Neurology.
1983;
33
1444-1452
-
20
McDonald W I, Compston A, Edan G, Goodkin D, Hartung H P, Lublin F D. et al .
Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis.
Ann Neurol.
2001;
50
121-127
-
21
Mikaeloff Y, Moreau T, Debouverie M, Pelletier J, Lebrun C, Gout O. et al .
Interferon-β treatment in patients with childhood-onset multiple sclerosis.
J Pediatr.
2001;
139
443-446
-
22
Pohl D, Hanefeld F.
Multiple Sklerose bei Kindern und Jugendlichen.
Akt Neurol.
2001;
28
8-11
-
23
Rosati G.
The prevalence of multiple sclerosis in the world: an update.
Neurol Sci.
2001;
22
117-139
-
24
Simone I L, Carrara D, Tortorella C, Liguori M, Lepore V, Pellegrini F. et al .
Course and prognosis in early-onset MS: comparison with adult-onset forms.
Neurology.
2002;
59
1922-1928
-
25
Sindern E, Haas J, Stark E, Wurster U.
Early onset MS under the age of 16: clinical and paraclinical features.
Acta Neurol Scand.
1992;
86
280-284
-
26
Steinman L.
Multiple sclerosis: a coordinated immunological attack against myelin in the central nervous system.
Cell.
1996;
85
299-302
-
27
van Walderveen M AA, Kamphorst W, Scheltens P, van Waesberghe J H, Ravid R, Valk J. et al .
Histopathologic correlate of hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis.
Neurology.
1998;
50
1282-1288
-
28
Waubant E, Hietpas J, Stewart T, Dyme Z, Herbert J, Lacy J. et al .
Interferon beta-1 a in children with multiple sclerosis is well tolerated.
Neuropediatrics.
2001;
32
211-213
-
29
Weinshenker B G.
Natural history of multiple sclerosis.
Ann Neurol.
1994;
36 (Suppl)
S6-S11
-
30
Wolinsky J S, Comi G, Filippi M, Ladkani D, Kadosh S, Shifroni G. The European/Canadian Glatiramer Acetate Study Group .
Copaxone's effect on MRI-monitored disease in relapsing MS is reproducible and sustained.
Neurology.
2002;
59
1284-1286
-
31
Ziemssen T, Neuhaus O, Hohlfeld R.
Risk-benefit assessment of glatiramer acetate in multiple sclerosis (review).
Drug Safety.
2001;
24
979-990
1 The authors contributed equally to the content of the paper
M. D. Barbara Kornek
Department of Neuropsychiatry of Childhood and Adolescence
University of Vienna
Währinger Gürtel 18 - 20
1090 Vienna
Austria
Email: barbara.kornek@univie.ac.at
